Literature DB >> 16647624

Urotensin II and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease.

Francesca Mallamaci1, Sebastiano Cutrupi, Patrizia Pizzini, Giovanni Tripepi, Carmine Zoccali.   

Abstract

BACKGROUND: Urotensin II (UTN), a cyclic undecapeptide widely distributed in various organs and tissues, is found in high concentration in atheromatous lesions. Because UTN accumulates in patients with chronic renal failure, the association between plasma UTN and biomarkers of atherosclerosis and endothelial activation needs to be better understood.
METHODS: We tested by a robust statistical approach (Holm method) the association between plasma UTN and biomarkers of atherosclerosis and endothelial activation in a population of 191 patients undergoing chronic hemodialysis.
RESULTS: Plasma UTN was significantly higher in patients with end-stage renal disease (median: 6.5 ng/mL) than in healthy subjects (median: 3.1 ng/mL) (P < .001), and in both patients and control subjects it was independent of age and sex. Interestingly, UTN was inversely related to fibrinogen (r = -0.50, P < .004), intracellular adhesion molecule-1 (r = -0.24, P < .004) and with NO synthesis inhibitor asymmetric dimethyl-arginine (r = -0.40, P < .004). These links were paralleled by direct correlations with albumin (r = 0.21, P < .006) and with transforming growth factor-beta1 (TGFbeta1) (r = 0.36, P < .004). Of note, on multiple regression analysis, these associations remained highly significant also after data adjustment for potential confounders.
CONCLUSIONS: The inverse links between UTN with biomarkers of atherosclerosis and endothelial activation suggest that downregulation of UTN may be a counter-regulatory response aimed at mitigating cardiovascular damage or that UTN itself is a protective factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647624     DOI: 10.1016/j.amjhyper.2005.10.019

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

Review 1.  Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review.

Authors:  Johannes Jacobi; Philip S Tsao
Journal:  Am J Nephrol       Date:  2007-10-24       Impact factor: 3.754

2.  Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.

Authors:  Joanna Leigh Dunlop; Alain Charles Vandal; Janak Rashme de Zoysa; Ruvin Sampath Gabriel; Imad Adbi Haloob; Christopher John Hood; Philip James Matheson; David Owen Ross McGregor; Kannaiyan Samuel Rabindranath; David John Semple; Mark Roger Marshall
Journal:  BMC Nephrol       Date:  2013-07-15       Impact factor: 2.388

3.  The relationship between urotensin II and its receptor and the clinicopathological parameters of breast cancer.

Authors:  Ozan Balakan; Mehmet Emin Kalender; Ali Suner; Beyhan Cengiz; Serdar Oztuzcu; Recep Bayraktar; Ersin Borazan; Taner Babacan; Celaletdin Camci
Journal:  Med Sci Monit       Date:  2014-08-12

4.  Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study.

Authors:  Anastasia Garoufi; Styliani Drapanioti; Antonios Marmarinos; Varvara Askiti; Andromachi J Mitsioni; Maria Mila; Georgia Grigoriadou; Dimitrios Georgakopoulos; Constantinos J Stefanidis; Dimitrios Gourgiotis
Journal:  BMC Nephrol       Date:  2017-03-31       Impact factor: 2.388

Review 5.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.